Technology | Transesophageal Echo (TEE) | June 20, 2017

Stroke2prevent Receives FDA 510(k) Clearance for A-View

Medical device uses TEE to visualize the aortic arch during cardiac interventions

Stroke2prevent Receives FDA 510(k) Clearance for A-View
Stroke2prevent Receives FDA 510(k) Clearance for A-View

June 20, 2017 — Dutch medical device company Stroke2prevent BV recently announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for A-View, a medical device used in cardiac interventions. The A-View balloon catheter visualizes the aortic arch with transesophageal echocardiography (TEE).

A-View is intended to resolve the so-called blind spot of TEE, caused by interposition of the trachea. The device is used to provide imaging of the entire aortic arch and has demonstrated to detect atherosclerosis, diagnose aortic diseases and to monitor vascular flow. The additional information obtained by A-View supports surgeons to ensure the best patient outcomes.

A-View is currently marketed in Europe and will become available in the U.S. soon, pending arrangements for a proper distribution and clinical support channel.

For more information: www.stroke2prevent.com


Additional Content

News | ASE

July 23, 2026 —The American Society of Echocardiography (ASE) and the ASE Foundation (ASEF) have named Nicholas Spetko ...

Home July 27, 2026
Home
News | ASE

July 2, 2026 — The American Society of Echocardiography (ASE) has announced the appointment of Cynthia C. Taub, MD, MBA ...

Home July 02, 2026
Home
News | ASE

June 15, 2026 — Nearly 2,000 cardiovascular imaging professionals from around the world will gather in Aurora, Colorado ...

Home June 15, 2026
Home
News | ASE

May 4, 2026 — A new guideline from the American Society of Echocardiography (ASE) provides guidance for cardiovascular ...

Home May 04, 2026
Home
News | ASE

June 12, 2024 — Royal Philips has announced its next-generation AI-enabled cardiovascular ultrasound platform to help ...

Home June 12, 2024
Home
Subscribe Now